Peripheral-blood GSH or GSSG is not a direct proxy for the central nervous system
It drives inflammation, insulin resistance, and cardiovascular risk, which is why targeting it has clear metabolic value
It also runs a safety panel covering eight hard-stop categories personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, current or recent severe gastrointestinal disease, severe pancreatitis history, active gallbladder disease, current pregnancy or breastfeeding, severe diabetic retinopathy, and a small set of other contraindications that would steer the conversation away from this class of therapy entirely
BPC-157
Finally, heterogeneity in study design, included populations (often mixing children and adolescents), supplement dosages and formulations, and even comparators (sometimes active placebos such as canola oil) complicates meta-analysis and explains divergent results, especially in functional gastroenterology (132137)
Before starting retatrutide (within a trial setting), your clinician should: Conduct a thorough medical history review , including assessment of conditions that may be trial exclusion criteria or require particular caution for example, a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2)